Prediction of S-1 adjuvant chemotherapy benefit in Stage II/III gastric cancer treatment based on comprehensive gene expression analysis
ConclusionsThe upregulation and enrichment of immune-related genes and GO terms may be predictive biomarkers in patients who would benefit from adjuvant S-1 chemotherapy to treat Stage II/III gastric cancer.
Source: Gastric Cancer - Category: Gastroenterology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Gastrectomy | Gastric (Stomach) Cancer | Gastroenterology | Genetics | Study